miR-205 regulates the proliferation and invasion of ovarian cancer cells via suppressing PTEN/SMAD4 expression

Chu,Ping; Liang,Aihua; Jiang,Aili; Zong,Lu

doi:10.3892/ol.2018.8313

miR-205 regulates the proliferation and invasion of ovarian cancer cells via suppressing PTEN/SMAD4 expression

Authors:
- Ping Chu
- Aihua Liang
- Aili Jiang
- Lu Zong
View Affiliations

Affiliations: Department of Gynecology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong 264100, P.R. China, Department of Gynecology and Obstetrics, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: March 21, 2018 https://doi.org/10.3892/ol.2018.8313
Pages: 7571-7578
Copyright: © Chu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs/miRs) are non‑coding RNAs that post‑transcriptionally control target genes, and are involved in tumorigenesis, apoptosis, proliferation, invasion, metastasis and chemoresistance. However, data concerning miRNAs in ovarian cancer remain incomplete. The present study aimed to identify miRNAs that affected the malignant phenotype of ovarian cancer, and to analyze their potential mechanisms. The data demonstrated that miR‑205 promoted cell proliferation and invasion of ovarian cancer cells via suppressing Phosphatase and tensin homolog (PTEN)/mothers against decapentaplegic homolog 4 (SMAD4) expression. Based on the Cancer Genome Atlas database analysis results, it was identified that miR‑205 was significantly upregulated in ovarian cancer tissues and markedly correlated with poor prognosis in patients with ovarian cancer; its abnormal expression was also confirmed in tissues from patients with ovarian cancer by reverse transcription quantitative polymerase chain reaction. Additional Gene Ontology analysis revealed that the target genes of miR‑205 were associated with cell proliferation and invasion. Consistent with the database analysis, miR‑205 overexpression significantly promoted ovarian cancer cell proliferation and invasion in vitro. To additionally explore the mechanism by which miR‑205 was associated with proliferation and invasion of ovarian cancer cells, a protein‑protein interaction network was constructed based on miR‑205 target genes associated with proliferation and invasion, and it was revealed that PTEN and SMAD4 were key target genes of miR‑205. In ovarian cancer tissues, the expression levels of PTEN and SMAD4 were significantly downregulated, suggesting that miR‑205 may suppress the expression of PTEN and SMAD4 in vivo. In vitro, miR‑205 overexpression markedly suppressed the expression of SMAD4 and PTEN, additionally verifying that PTEN and SMAD4 were the target genes of miR‑205 in ovarian cancer cells. These results elucidated the tumor‑promoting role of miR‑205 and established miR‑205 as a potential treatment target for ovarian cancer.

View Figures

View References

1	Webb PM and Jordan SJ: Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 41:3–14. 2017. View Article : Google Scholar : PubMed/NCBI
2	Mahdian-Shakib A, Dorostkar R, Tat M, Hashemzadeh MS and Saidi N: Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer. Biomed Pharmacother. 84:592–600. 2016. View Article : Google Scholar : PubMed/NCBI
3	Yu G, Jia Z and Dou Z: miR-24-3p regulates bladder cancer cell proliferation, migration, invasion and autophagy by targeting DEDD. Oncol Rep. 37:1123–1131. 2017. View Article : Google Scholar : PubMed/NCBI
4	Ma Q, Peng Z, Wang L, Li Y, Wang K, Zheng J, Liang Z and Liu T: miR-19a correlates with poor prognosis of clear cell renal cell carcinoma patients via promoting cell proliferation and suppressing PTEN/SMAD4 expression. Int J Oncol. 49:2589–2599. 2016. View Article : Google Scholar : PubMed/NCBI
5	Fu X, Li Y, Alvero A, Li J, Wu Q, Xiao Q, Peng Y, Hu Y, Li X, Yan W, et al: MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival. Oncotarget. 7:80633–80654. 2016. View Article : Google Scholar : PubMed/NCBI
6	Jeong JY, Kang H, Kim TH, Kim G, Heo JH, Kwon AY, Kim S, Jung SG and An HJ: MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3. Cancer Lett. 386:168–178. 2017. View Article : Google Scholar : PubMed/NCBI
7	Tian S, Zhang M, Chen X, Liu Y and Lou G: MicroRNA-595 sensitizes ovarian cancer cells to cisplatin by targeting ABCB1. Oncotarget. 7:87091–87099. 2016. View Article : Google Scholar : PubMed/NCBI
8	Zhou F, Chen J and Wang H: MicroRNA-298 inhibits malignant phenotypes of epithelial ovarian cancer by regulating the expression of EZH2. Oncol Lett. 12:3926–3932. 2016. View Article : Google Scholar : PubMed/NCBI
9	Hu K and Liang M: Upregulated microRNA-224 promotes ovarian cancer cell proliferation by targeting KLLN. In Vitro Cell Dev Biol Anim. 53:149–156. 2017. View Article : Google Scholar : PubMed/NCBI
10	Liang T, Li L, Cheng Y, Ren C and Zhang G: MicroRNA-194 promotes the growth, migration, and invasion of ovarian carcinoma cells by targeting protein tyrosine phosphatase nonreceptor type 12. Onco Targets Ther. 9:4307–4315. 2016. View Article : Google Scholar : PubMed/NCBI
11	Wu AH, Huang YL, Zhang LZ, Tian G, Liao QZ and Chen SL: MiR-572 prompted cell proliferation of human ovarian cancer cells by suppressing PPP2R2C expression. Biomed Pharmacother. 77:92–97. 2016. View Article : Google Scholar : PubMed/NCBI
12	Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al: The STRING database in 2017: Quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 45(D1): D362–D368. 2017. View Article : Google Scholar : PubMed/NCBI
13	Marko TA, Shamsan GA, Edwards EN, Hazelton PE, Rathe SK, Cornax I, Overn PR, Varshney J, Diessner BJ, Moriarity BS, et al: Slit-Robo GTPase-activating protein 2 as a metastasis suppressor in osteosarcoma. Sci Rep. 6:390592016. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Ito N, Sakai A, Miyake N, Maruyama M, Iwasaki H, Miyake K, Okada T, Sakamoto A and Suzuki H: miR-15b mediates oxaliplatin-induced chronic neuropathic pain through BACE1 downregulation. Br J Pharmacol. 174:386–395. 2017. View Article : Google Scholar : PubMed/NCBI
16	Hu Y, Qiu Y, Yagüe E, Ji W, Liu J and Zhang J: miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer. Cell Death Dis. 7:e22912016. View Article : Google Scholar : PubMed/NCBI
17	Cañueto J, Cardeñoso-Álvarez E, García-Hernández JL, Galindo-Villardón P, Vicente-Galindo P, Vicente-Villardón JL, Alonso-López D, De Las Rivas J, Valero J, Moyano-Sanz E, et al: MicroRNA (miR)-203 and miR-205 expression patterns identify subgroups of prognosis in cutaneous squamous cell carcinoma. Br J Dermatol. 177:168–178. 2017. View Article : Google Scholar : PubMed/NCBI
18	Osipov ID, Zaporozhchenko IA, Bondar AA, Zaripov MM, Voytsitskiy VE, Vlassov VV, Laktionov PP and Morozkin ES: Cell-free miRNA-141 and miRNA-205 as prostate cancer biomarkers. Adv Exp Med Biol. 924:9–12. 2016. View Article : Google Scholar : PubMed/NCBI
19	Pan F, Mao H, Bu F, Tong X, Li J, Zhang S, Liu X, Wang L, Wu L, Chen R, et al: Sp1-mediated transcriptional activation of miR-205 promotes radioresistance in esophageal squamous cell carcinoma. Oncotarget. 8:5735–5752. 2017.PubMed/NCBI
20	Torres A, Kozak J, Korolczuk A, Rycak D, Wdowiak P, Maciejewski R and Torres K: Locked nucleic acid-inhibitor of miR-205 decreases endometrial cancer cells proliferation in vitro and in vivo. Oncotarget. 7:73651–73663. 2016. View Article : Google Scholar : PubMed/NCBI
21	Wang X, Yu M, Zhao K, He M, Ge W, Sun Y, Wang Y, Sun H and Hu Y: Upregulation of MiR-205 under hypoxia promotes epithelial-mesenchymal transition by targeting ASPP2. Cell Death Dis. 7:e25172016. View Article : Google Scholar : PubMed/NCBI
22	Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et al: MicroRNA signatures in human ovarian cancer. Cancer Res. 67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
23	Niu K, Shen W, Zhang Y, Zhao Y and Lu Y: MiR-205 promotes motility of ovarian cancer cells via targeting ZEB1. Gene. 574:330–336. 2015. View Article : Google Scholar : PubMed/NCBI
24	Li J, Li L, Li Z, Gong G, Chen P, Liu H, Wang J, Liu Y and Wu X: The role of miR-205 in the VEGF-mediated promotion of human ovarian cancer cell invasion. Gynecol Oncol. 137:125–133. 2015. View Article : Google Scholar : PubMed/NCBI
25	Li J, Hu K, Gong G, Zhu D, Wang Y, Liu H and Wu X: Upregulation of MiR-205 transcriptionally suppresses SMAD4 and PTEN and contributes to human ovarian cancer progression. Sci Rep. 7:413302017. View Article : Google Scholar : PubMed/NCBI